Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07558395

Effectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour

Evaluate the efficiency of audiovisual stimulation in virtual reality for improving the visual perception of children, adolescents, and young adults with hemianopia resulting from pediatric brain tumors. These individuals can lose up to 50% of their visual field, significantly impacting their independence, mobility, and daily lives.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Hemianopsia Blindness Brain Diseases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Eye Diseases Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms Neurologic Manifestations Pathological Conditions, Signs and Symptoms Pediatric Brain Tumor Sensation Disorders Signs and Symptoms Virtual Reality Vision Disorders Visual Rehabilitation

Age range

10 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Paediatric and adolescents medicine, Medical University, Vienna, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and Female
  • 10 - 40 years old
  • Diagnosed hemianopsia (>12 months)
  • History of diagnosis brain tumour
  • Being stable for the tumour for > 6 months (either on therapy or not)
  • Visual acuity ≤ 0.7 LogMAR
  • Ability to follow the visual and auditory stimuli and training instructions
  • Home WiFi access
  • Ability to attend all on site visits
  • Affiliation to the Social Security or beneficiary of such social protection

Exclusion criteria

  • Age< 10 years old of > 40 years old
  • Ocular disease
  • Inability to perform during testing or training
  • 3 consecutive VRISE scores < 25 at inclusion
  • History of vertigo
  • Prior vision rehabilitation interventions
  • Recreational or medicinal consumption of psychoactive drugs
  • Persons under court protection
  • Interpupillary distance < 54mm

Treatment and study plan

Visual Stimulation

Device

Our audiovisual stimulation procedure IVR, called 3D-MOT, was encoded using the the 3D Unity programming platform and deployed in HMDs with built-in head/eye tracking. We implemented the multiple object tracking (MOT) paradigm, developed in the 80's to study visual attention in humans, and added correlated spatial sound.

Standard of care

Other

During this phase, the patients will be at home without a headset and will not be exposed to an audio-visual stimulation task in virtual reality.

Primary outcomes

  1. Visual field perimetry measured using the Esterman binocular field test

    Time frame: From enrollment to the end of follow up period at 6 months

    Increase at least 3 points in the number of points perceived in the blind field at the Esterman binocular field test after intervention (8 weeks) when compared to baseline and between control and interventional group.

Secondary outcomes

  1. Participant-reported a vision impairment specific quality of life questionnaire: Impact of Vision Impairment Questionnaire (IVI).

    Time frame: From enrollment to the end of follow up period at 6 months

    Questionnaire will be provided and compared at baseline and after intervention ( 8 weeks) and between control and interventional group.

    A diminution of the mean score above 0.3-0.5 point will be consider as an amelioration of quality of life impacted by vision impairment.

  2. Reading speed - Minnesota Low Vision Reading (MNREAD) test

    Time frame: From enrollment to the end of follow up period at 6 months

    Reading speed will be assessed and compared at baseline and after intervention (8 weeks) and between control and interventional groups. An increase in reading speed of 8.6 words per minute on the Minnesota Low Vision Reading (MNREAD) test will be considered an improvement in the variable.

Study contacts

Contact information is provided by the study sponsor or research team.

Michael Reber, PhD

CONTACT

[email protected]

+33 388116648 ext. 17675

Natacha Entz-Werle, Pr

CONTACT

[email protected]

0388128396

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Collaborators

  • Fight Kids Cancer

Registry information

Acronym: REVIIH-BT

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Apr 30, 2026
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.